Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.
Anita J BroganAshley E DavisClaire E MellottJeremy FraysseAimee A MetznerAlan K OglesbyPublished in: PharmacoEconomics (2024)
Our analysis suggests that initiating CAB-LA for PrEP is cost-effective versus generic daily oral FTC/TDF for individuals at risk of acquiring HIV-1 infection.